On Monday, BioNTech SE BNTX reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a yr in the past.
The upper revenues within the third quarter had been largely attributed to the sooner approvals obtained for its variant-adapted COVID-19 vaccines in comparison with final yr.
The COVID-19 vaccine maker reported a third-quarter internet revenue of 198.1 million euros, up from 160.6 million euros a yr in the past. BioNTech reported EPS of 81 cents, up from 66 a yr in the past.
“We efficiently launched our variant-adapted COVID-19 vaccines upon receipt of earlier approvals as in comparison with final yr. This drove our robust revenues within the third quarter,” mentioned Jens Holstein, CFO of BioNTech
Additionally Learn: FDA Presses Scientific Maintain Button For BioNTech’s Companion Late-Stage Trial Of Investigational Lung Most cancers Remedy
Steering: BioNTech expects its revenues for the total 2024 monetary yr to be on the low finish of the steerage vary supplied in its outlook of two.5 billion euros- 3.1 billion euros
The vary displays sure assumptions and expectations, together with COVID-19 vaccine uptake and worth ranges.
For 2024, the corporate has diminished its earlier steerage for anticipated SG&A bills from 700 million euros- 800 million euros to 600 million euros- 700 million euros.
The corporate expects capital expenditures of 300 million euros – 400 million euros, down from prior steerage of 400 million euros – 500 million euros.
Worth Motion: BNTX inventory is down 2.70% at $108.47 on the final verify on Monday.
Learn Subsequent:
Picture through Wikimedia Commons
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
